drugset / Trial / NCT01538420

GLPG0492 Pharmacodynamics

NCT01538420 ↗

Phase 1 Completed 26 enrolled Lakefront Biotherapeutics NV
RandomizedParallel-groupQuadruple-blindTreatment

Summary

GLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g. after orthopedic surgery) or due to aging (androgenic effect), but without anabolic effects (e.g. effect on testosterone). In the first part of the current study it will be tested whether GLPG0492 given orally to healthy male volunteers increases the protein synthesis in muscle, as measured by the uptake into the muscle of intravenously infused phenylalanine. In the second part of the study, the effect of the compound on the "hormone household" in healthy, postmenopausal women will be assessed.

Timeline

Start
2012-01
Primary completion
2012-03
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG0492 Small molecule 0.5 mg Oral

Indications

No indication recorded.